Magazine Article | March 8, 2017

Grünenthal's Plan To Grow Globally & Expand Its Pipeline

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

The private, European-based company widens its base with new approaches and technologies for treating pain and, now, related conditions.

If you can spot it through the dense cloud of opioid- epidemic news currently emanating from the United States, some companies are developing new modalities for the treatment of pain. Among them, Grünenthal is a recognized catalyst. Like other pain-focused companies, Grünenthal has mainly pursued innovation with “abuse-deterrent” technologies and products for the prescription-opioid market. But now, along with a slew of partners, the company is identifying, studying, and targeting specific types, or “segments,” of pain, using new therapeutic mechanisms and technologies — even developing novel, non-opioid applications for its abuse-deterrent INTAC platform. It is also moving beyond pain into other, “adjacent,” areas.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.